Arcus Biosciences, Inc. reported impairment of long-lived assets for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $20 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.95 USD | +5.84% | +2.23% | -16.13% |
05:42pm | Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating | MT |
10:35am | Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.13% | 1.37B | |
+45.95% | 54.63B | |
-6.94% | 39.92B | |
+37.07% | 38.82B | |
+13.17% | 26.86B | |
-11.17% | 26.22B | |
-21.71% | 18.78B | |
+24.94% | 12.21B | |
+0.53% | 12.16B | |
+25.09% | 11.94B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024